PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS
Purpose. Pharmacoeconomic rationale for the use of sorafenib in malignant tumors in comparison with drugs that are included in the list of pharmaceuticals to provide to certain categories of citizens.Method of the study. Pharmacoeconomic rationale for the use of sorafenib in this study is made by an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2016-09-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568616013266944 |
|---|---|
| author | M. Y. Frolov N. A. Avksentjev I. G. Rusakov E. V. Derkach |
| author_facet | M. Y. Frolov N. A. Avksentjev I. G. Rusakov E. V. Derkach |
| author_sort | M. Y. Frolov |
| collection | DOAJ |
| description | Purpose. Pharmacoeconomic rationale for the use of sorafenib in malignant tumors in comparison with drugs that are included in the list of pharmaceuticals to provide to certain categories of citizens.Method of the study. Pharmacoeconomic rationale for the use of sorafenib in this study is made by analyzing the impact on the budget. The calculated costs of treatment with sorafenib at a hypothetical group of 100 patients with metastatic renal cell carcinoma (MRCC), hepatocellular carcinoma (HCC) and differentiated thyroid cancer resistant to radioactive iodine (DCT). These costs were compared with costs of treatment of a similar group of 100 patients, with treatment of MRCC applied bevacizumab (original or generic) in combination with interferon α, and patients with HCC and DCT were excluded from receiving drugs from a program of providing with necessary medicines (PNM). As a result the potential economic effect of the inclusion of sorafenib in the list of PNM was calculated.Results. Treatment of MRCC is cheaper with the use of sorafenib compared to bevacizumab in combination with interferon α: savings is 592 878 rubles in the original use of bevacizumab and 274 976 rubles in the use of generic bevacizumab for one patient-year. If we use sorafenib in a group of 100 people with MRCC, HCC and DCT suitable for treatment with sorafenib, the overall expenses are more than 175 million rubles, while using the original combination of bevacizumab with interferon α – more than 204 million rubles, and in the application of the generic combination of bevacizumab with interferon α – more than 176 million rubles, while in the two last cases the treatment of patients with HCC and DCT is not carried out. The total amount of annual budget savings in the treatment of 100 patients is more than 28.5 million rubles at the account of original of bevacizumab or more than 1 million rubles in accounting of generic bevacizumab.Conclusion. The inclusion of the targeted drug sorafenib in the list of pharmaceuticals to provide certain categories of citizens is economically justified. The use of sorafenib, instead of the combination of bevacizumab + interferon-α in patients with MRCC gives us the opportunity to release the funds and provide a systemic treatment of patients with other malignancies (HCC, DCT) while reducing the burden on the budget. |
| format | Article |
| id | doaj-art-0f4052eb503e4f34b96f2b25042be11b |
| institution | Kabale University |
| issn | 2410-1893 |
| language | Russian |
| publishDate | 2016-09-01 |
| publisher | QUASAR, LLC |
| record_format | Article |
| series | Исследования и практика в медицине |
| spelling | doaj-art-0f4052eb503e4f34b96f2b25042be11b2025-02-03T00:57:39ZrusQUASAR, LLCИсследования и практика в медицине2410-18932016-09-013381610.17709/2409-2231-2016-3-3-1110PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORSM. Y. Frolov0N. A. Avksentjev1I. G. Rusakov2E. V. Derkach3Volgograd State Medical University (Volgograd, Russia). 1, ploshchad’ Pavshikh Bortsov, Volgograd, 400131, Russia Association of clinical pharmacologists (Volgograd, Russia). 1, ploshchad’ Pavshikh Bortsov, Volgograd, 400131, RussiaScientific and research financial institute (Moscow, Russia). 3/2, Nastas’inskii per., Moscow, 127006, Russia The Russian Presidential Academy оf National Economy аnd Public Administration (Moscow, Russia). 84/2, pr. Vernadskogo, Moscow, 119571, RussiaCity clinical hospital №57, of the Department of health of Mos cow (Moscow, Russia). 32, ul. 11-ya Parkovaya, Moscow, 105077, RussiaThe Russian Presidential Academy оf National Economy аnd Public Administration (Moscow, Russia). 84/2, pr. Vernadskogo, Moscow, 119571, Russia Center for technology assessment in health care (Moscow , Russia). P.O. Box 88, Moscow, 117335, RussiaPurpose. Pharmacoeconomic rationale for the use of sorafenib in malignant tumors in comparison with drugs that are included in the list of pharmaceuticals to provide to certain categories of citizens.Method of the study. Pharmacoeconomic rationale for the use of sorafenib in this study is made by analyzing the impact on the budget. The calculated costs of treatment with sorafenib at a hypothetical group of 100 patients with metastatic renal cell carcinoma (MRCC), hepatocellular carcinoma (HCC) and differentiated thyroid cancer resistant to radioactive iodine (DCT). These costs were compared with costs of treatment of a similar group of 100 patients, with treatment of MRCC applied bevacizumab (original or generic) in combination with interferon α, and patients with HCC and DCT were excluded from receiving drugs from a program of providing with necessary medicines (PNM). As a result the potential economic effect of the inclusion of sorafenib in the list of PNM was calculated.Results. Treatment of MRCC is cheaper with the use of sorafenib compared to bevacizumab in combination with interferon α: savings is 592 878 rubles in the original use of bevacizumab and 274 976 rubles in the use of generic bevacizumab for one patient-year. If we use sorafenib in a group of 100 people with MRCC, HCC and DCT suitable for treatment with sorafenib, the overall expenses are more than 175 million rubles, while using the original combination of bevacizumab with interferon α – more than 204 million rubles, and in the application of the generic combination of bevacizumab with interferon α – more than 176 million rubles, while in the two last cases the treatment of patients with HCC and DCT is not carried out. The total amount of annual budget savings in the treatment of 100 patients is more than 28.5 million rubles at the account of original of bevacizumab or more than 1 million rubles in accounting of generic bevacizumab.Conclusion. The inclusion of the targeted drug sorafenib in the list of pharmaceuticals to provide certain categories of citizens is economically justified. The use of sorafenib, instead of the combination of bevacizumab + interferon-α in patients with MRCC gives us the opportunity to release the funds and provide a systemic treatment of patients with other malignancies (HCC, DCT) while reducing the burden on the budget.https://www.rpmj.ru/rpmj/article/view/146renal cell carcinomahepatocellular carcinomathyroid carcinomabevacizumabinterferon-sorafenibprogram of providing with necessary medicineslist of drugs for provision of certain categories of citizens |
| spellingShingle | M. Y. Frolov N. A. Avksentjev I. G. Rusakov E. V. Derkach PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS Исследования и практика в медицине renal cell carcinoma hepatocellular carcinoma thyroid carcinoma bevacizumab interferon- sorafenib program of providing with necessary medicines list of drugs for provision of certain categories of citizens |
| title | PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS |
| title_full | PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS |
| title_fullStr | PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS |
| title_full_unstemmed | PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS |
| title_short | PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS |
| title_sort | pharmacoeconomical research of the use of sorafenib in malignant tumors |
| topic | renal cell carcinoma hepatocellular carcinoma thyroid carcinoma bevacizumab interferon- sorafenib program of providing with necessary medicines list of drugs for provision of certain categories of citizens |
| url | https://www.rpmj.ru/rpmj/article/view/146 |
| work_keys_str_mv | AT myfrolov pharmacoeconomicalresearchoftheuseofsorafenibinmalignanttumors AT naavksentjev pharmacoeconomicalresearchoftheuseofsorafenibinmalignanttumors AT igrusakov pharmacoeconomicalresearchoftheuseofsorafenibinmalignanttumors AT evderkach pharmacoeconomicalresearchoftheuseofsorafenibinmalignanttumors |